BIOPHARMCONSORTIUM.COM
Haberman Associates – Consulting for Effective Life Science R&D and PartneringConsulting for Effective Life Science R&D and Partnering
http://www.biopharmconsortium.com/
Consulting for Effective Life Science R&D and Partnering
http://www.biopharmconsortium.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
8 seconds
16x16
32x32
64x64
128x128
160x160
192x192
256x256
PERFECT PRIVACY, LLC
12808 Gra●●●●●●●●●kway West
Jack●●●●ille , FL, 32258
US
View this contact
PERFECT PRIVACY, LLC
12808 Gra●●●●●●●●●kway West
Jack●●●●ille , FL, 32258
US
View this contact
PERFECT PRIVACY, LLC
12808 Gra●●●●●●●●●kway West
Jack●●●●ille , FL, 32258
US
View this contact
BUY YOUR DOMAIN
25
YEARS
11
MONTHS
3
DAYS
NETWORK SOLUTIONS, LLC.
WHOIS : whois.networksolutions.com
REFERRED : http://networksolutions.com
PAGES IN
THIS WEBSITE
13
SSL
EXTERNAL LINKS
31
SITE IP
75.98.175.116
LOAD TIME
8.027 sec
SCORE
6.2
Haberman Associates – Consulting for Effective Life Science R&D and Partnering | biopharmconsortium.com Reviews
https://biopharmconsortium.com
Consulting for Effective Life Science R&D and Partnering
biopharmconsortium.com
Haberman Associates - Our Publications
https://biopharmconsortium.com/our-publications
Consulting for Effective Life Science R&D and Partnering. Allan B. Haberman, Ph.D. Allan B. Haberman, Ph.D. Publications are designed to help you understand and act on the ever-changing science, technology, market, and strategic issues that affect the life science industry. They also help you assess leading companies and their products and technologies. Our publications include in-depth research and analysis in:. Business strategy in the pharmaceutical, biotechnology, and life science industry. Cancer Im...
Immune checkpoint inhibitors work by reactivating tumor-infiltrating T cells (TILs) - Biopharmconsortium Blog
https://biopharmconsortium.com/2014/12/15/immune-checkpoint-inhibitors-work-by-reactivating-tumor-infiltrating-t-cells-tils
Consulting for Effective Life Science R&D and Partnering. Allan B. Haberman, Ph.D. Allan B. Haberman, Ph.D. Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Immune checkpoint inhibitors work by reactivating tumor-infiltrating T cells (TILs). Immune checkpoint inhibitors work by reactivating tumor-infiltrating T cells (TILs). December 15, 2014. The 27 November issue of. These studies are described in five papers published in that issue of. And Herbst et al. Contain r...
Haberman Associates - News Archive 2012
https://biopharmconsortium.com/news-archive-2012
Consulting for Effective Life Science R&D and Partnering. Allan B. Haberman, Ph.D. Allan B. Haberman, Ph.D. November 19, 2012:. Allan B. Haberman, Ph.D. Was quoted in an article in. Chemical and Engineering News. C&EN) by senior editor Lisa M Jarvis. The article is entitled Agios Takes A Long View In Cell Metabolism. For a commentary on issues raised by this C&EN article, see our Biopharmconsortium Blog. April 13, 2012:. Informa’s Scrip Insights announced the publication of a new book-length report,.
Haberman Associates - About Haberman Associates
https://biopharmconsortium.com/about-haberman-associates
Consulting for Effective Life Science R&D and Partnering. Allan B. Haberman, Ph.D. Allan B. Haberman, Ph.D. We consult, write, and speak on critical issues that determine the success of life science companies. Working together with our partners in the Biopharmaceutical Consortium. And Innovalyst, we help your company increase the effectiveness of its drug and diagnostic discovery and development, commercialization of new research products, assessment of new business opportunities, and partnering. Our pri...
Haberman Associates - Biopharmconsortium Blog
https://biopharmconsortium.com/blog
Consulting for Effective Life Science R&D and Partnering. Allan B. Haberman, Ph.D. Allan B. Haberman, Ph.D. Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Strimvelis (GSK2696273), a gene therapy for a deadly immunodeficiency in children, expected to reach the European market in mid-2016. April 21, 2016. Our recent book-length report,. Gene Therapy: Moving Toward Commercialization. One of these products, uniQure/Chiesi’s Glybera (alipogene tiparvovec), a treatment ...
TOTAL PAGES IN THIS WEBSITE
13
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: July 2009
http://biopharmconsortium.blogspot.com/2009_07_01_archive.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Tuesday, July 28, 2009. Now for some chemistry—Natural Products. In the 10 July issue of Science, Jesse W.-H. Li and John C. Vederas of the University of Alberta reviewed the current state of natural products-based drug discovery and development, in a report entitled “Drug Discovery and Natural Products: End of an Era or an Endless Frontier? Among the technologies that the authors discuss is an application of syntheti...
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: May 2010
http://biopharmconsortium.blogspot.com/2010_05_01_archive.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Thursday, May 13, 2010. A frog jumps into the animal model lineup. The cover of the 30 April 2010 issue of Science. Bears a photo of a tadpole of the western clawed frog Xenopus tropicalis. In that issue is a report. On the draft sequence of the genome of this organism, and a short companion news feature. The report on the genome emphasizes X. tropicalis’. Published by Cambridge Healthtech Institute in March 2010.
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: April 2010
http://biopharmconsortium.blogspot.com/2010_04_01_archive.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Friday, April 23, 2010. Agios Pharmaceuticals partners with Celgene. On December 31, 2009, we posted an article. On this blog about Agios Pharmaceuticals. On April 15, 2010, it was announced that Agios and Celgene Corporation. Summit, NJ), a public biotechnology company with marketed products, had formed a strategic collaboration in the area of cancer metabolism. The goal of the Agios/Celgene collaboration is to disco...
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: Developing improved mouse models of cancer for drug discovery and development
http://biopharmconsortium.blogspot.com/2010/04/developing-improved-mouse-models-of.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Thursday, April 15, 2010. Developing improved mouse models of cancer for drug discovery and development. The April 1, 2010 issue of The Scientist. Has an article, entitled “Building a better mouse”. On efforts of researchers to develop improved mouse models of cancer. Article focuses on the ongoing “co-clinical mouse/human trials”. The human clinical trials being “shadowed” by simultaneous studies in mice ...Transgene...
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: January 2010
http://biopharmconsortium.blogspot.com/2010_01_01_archive.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Thursday, January 28, 2010. Update on liraglutide (Novo Nordisk’s Victoza)—approved by the FDA for treatment of type 2 diabetes. On October 25, 2009, we posted an article. On January 26, 2010, after a 21-month review, the FDA approved liraglutide for treatment of type 2 diabetes. This followed the approval of the drug in Japan a week earlier. As a result, the drug’s label carries a black box warning of the risk ...
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: A frog jumps into the animal model lineup
http://biopharmconsortium.blogspot.com/2010/05/frog-jumps-into-animal-model-lineup.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Thursday, May 13, 2010. A frog jumps into the animal model lineup. The cover of the 30 April 2010 issue of Science. Bears a photo of a tadpole of the western clawed frog Xenopus tropicalis. In that issue is a report. On the draft sequence of the genome of this organism, and a short companion news feature. The report on the genome emphasizes X. tropicalis’. Published by Cambridge Healthtech Institute in March 2010.
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: Some notes on acute promyelocytic leukemia (APL)
http://biopharmconsortium.blogspot.com/2010/04/some-notes-on-acute-promyelocytic.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Monday, April 19, 2010. Some notes on acute promyelocytic leukemia (APL). In our last blog post. What once was an invariably fatal disease now has about a 90% survival rate. For those of you who are interested in the mechanisms by which ATRA and As. Work in treatment of APL: the 9 April 2010 issue of Science. And a research report. That focus on the mechanistic basis for the action of As. Published in Nature Medicine.
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: December 2009
http://biopharmconsortium.blogspot.com/2009_12_01_archive.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Thursday, December 31, 2009. Cancer metabolism as a target for drug discovery: Agios Pharmaceuticals. In the December 10 2009 issue of Nature. Researchers at Agios Pharmaceuticals (Cambridge, MA) and their academic collaborators published an article. Implicating mutations in a metabolic enzyme, cytosolic isocitrate dehydrogenase (IDH1) as a causative factor in a major subset of human brain cancers. According to the au...
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: February 2010
http://biopharmconsortium.blogspot.com/2010_02_01_archive.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Friday, February 19, 2010. Across-the-board R&D cuts will not solve the pharmaceutical industry’s productivity crisis. The big topic in pharmaceutical news lately has been layoffs, including layoffs due to major cuts in R&D. For example, the popular pharmaceutical industry blog “In the Pipeline”. The more fundamental reason that motivates large pharmaceutical companies to enter into big mergers and/or to undertake res...
biopharmconsortium.blogspot.com
Biopharmconsortium Blog: November 2009
http://biopharmconsortium.blogspot.com/2009_11_01_archive.html
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Friday, November 27, 2009. Stapled peptides for targeting intracellular signaling pathways: research and commercial development. In the 12 November issue of Nature. There was a research article. And a News and Views minireview. About targeting an intracellular signaling pathway with a novel type of compound called a stapled peptide. However, the 12 November Nature. The signaling pathway that is the focus of this artic...
TOTAL LINKS TO THIS WEBSITE
31
Default Parallels Plesk Panel Page
Web Server's Default Page. This page is generated by Parallels Plesk Panel. The leading hosting automation software. You see this page because there is no Web site at this address. You can do the following:. For more information please contact . Parallels is a worldwide leader in virtualization and automation software that optimizes computing for consumers, businesses, and Cloud services providers across all major hardware, operating systems, and virtualization platforms. To find out more information.
biopharm2-kinshasa
Biopharmconllc.com
ExecServices
Is a National Full Service Recruiting Organization. Functional expertise encompasses Business Development, Clinical Research, Commercial, Drug Safety, Marketing, Medical/Scientific Affairs and Regulatory Affairs. Because this is our only business, we are able to find and attract the most qualified candidates for your open positions. Reduced Time to Hire, Increased Quality of Candidates and Reduced Cost per Hire. Are three of the most widely tracked metrics in our industry today. With BioPharmConnect.
biopharmconsortium.blogspot.com
Biopharmconsortium Blog
Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting. Friday, June 11, 2010. Haberman Associates' Biopharmconsortium Blog has moved to our own site. You can now find it at http:/ biopharmconsortium.com/blog. Please go to the new site, which has many new posts on it. We invite you to keep reading our blog, to subscribe to it, and to make useful comments to our blog posts if you so desire. Allan B Haberman, Ph.D. Links to this post. Saturday, June 5, 2010. We hope that you...
Haberman Associates – Consulting for Effective Life Science R&D and Partnering
Consulting for Effective Life Science R&D and Partnering. About Allan B. Haberman, Ph.D. About Allan B. Haberman, Ph.D. From drug discovery research . . . We can help you navigate your path to more productive R and D. Consulting for effective life science R&D and partnering. Is a Boston-based consulting firm, founded in 1993, that specializes in science and technology strategy for biotechnology, pharmaceutical, and other life science companies. Clients have used our consulting services to help them:.
BioPharmConsult AG - Management and Engineering Services
*** DomainRegistry.com Inc. ***
By DomainRegistry.Com Inc. CouponBook.com - Coupons, Discounts. BusinessForms.com - Business Forms.
Price Request - BuyDomains
Url=' escape(document.location.href) , 'Chat367233609785093432', 'toolbar=0,scrollbars=0,location=0,statusbar=0,menubar=0,resizable=0,width=640,height=500');return false;". Need a price instantly? Just give us a call. Toll Free in the U.S. We can give you the price over the phone, help you with the purchase process, and answer any questions. Get a price in less than 24 hours. Fill out the form below. One of our domain experts will have a price to you within 24 business hours. United States of America.
biopharmcro.com - Registered at Namecheap.com
This domain is registered at Namecheap. This domain was recently registered at Namecheap. Please check back later! This domain is registered at Namecheap. This domain was recently registered at Namecheap. Please check back later! The Sponsored Listings displayed above are served automatically by a third party. Neither Parkingcrew nor the domain owner maintain any relationship with the advertisers.
Bio Pharm Deals
For links and comments on bio/pharma deal making and investment, visit us on twitter : @biopharmdeals. For resources for business development professionals, visit our resource pages - links above. BioPharm Deals tracks trends, strategies and resources in biotech and pharma business development and licensing.
SOCIAL ENGAGEMENT